FDA Awards Fast-track Status to Sangamo’s Investigational Gene Therapy SB-525 for Hemophila A – Hemophilia News Today
|
FDA Awards Fast-track Status to Sangamo's Investigational Gene Therapy SB-525 for Hemophila A
Hemophilia News Today The U.S. Food and Drug Administration (FDA) has granted fast-track status to SB-525, a clinical gene therapy for hemophilia A developed by Sangamo Therapeutics in partnership with Pfizer. SB-525 delivers a human factor VIII cDNA construct and synthetic … |
